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The addition of oral capecitabine to docetaxel improves response rate, time to progression (TTP) and overall survival in
anthracycline-pretreated metastatic breast cancer (MBC). This phase II study evaluates the efficacy and safety of a 21-day cycle of oral
capecitabine (1000mgm
 2 twice daily, days 1–14) plus i.v. paclitaxel (175mgm
 2, day 1) in anthracycline-pretreated advanced/
MBC. In all, 73 patients were enrolled at 13 Swedish and Spanish centres. The objective response rate was 52% (95% confidence
interval (CI): 40–63%) in the intent-to-treat population, including complete responses in 11%. Disease was stabilised in a further 29%.
The median time to disease progression (TTP) was 8.1 months and the median overall survival was 16.5 months. The combination
was generally well tolerated with a predictable safety profile. The most common treatment-related nonhaematological adverse
events were hand–foot syndrome (42%), alopecia (30%) and diarrhoea (26%). The only treatment-related Grade 3/4 adverse events
occurring in 45% of patients were alopecia (22%) and hand–foot syndrome (11%). Grade 3/4 neutropenia and lymphocytopenia
were reported in 12 and 14% of patients, respectively. Capecitabine plus paclitaxel is highly active with a favourable safety profile in
anthracycline-pretreated MBC.
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Systemic cytotoxic chemotherapy is the treatment of choice for
patients with advanced/metastatic breast cancer (MBC) that is
hormone resistant, oestrogen/progesterone-receptor negative, or
shows evidence of rapid progression, particularly in visceral sites.
The majority of patients receive an anthracycline-based regimen as
their first chemotherapy treatment for breast cancer, in either the
(neo)adjuvant or metastatic setting. For patients whose disease has
progressed during or following treatment with anthracyclines,
single-agent docetaxel was, until recently, the standard of care,
based on a survival advantage compared with mitomycin C plus
vinblastine observed in a randomised phase III trial (Nabholtz et al,
1999). No combination regimen had been shown to improve
outcomes compared with single-agent docetaxel, until a phase III
study demonstrated that the addition of the oral fluoropyrimidine
capecitabine (Xeloda
s: F Hoffmann-La Roche, Basel, Switzerland)
to docetaxel improves response rates, time to progression (TTP)
and, most importantly, overall survival in patients with anthracy-
cline-pretreated MBC (O’Shaughnessy et al, 2002). In light of these
findings, we report here the results of a phase II study evaluating
capecitabine in combination with paclitaxel (Taxol
s: Bristol-
Myers Squibb Company, New Jersey, USA) in patients with
anthracycline-pretreated MBC.
Oral capecitabine generates 5-fluorouracil (5-FU) preferentially
in tumour tissue by exploitation of the increased activity of
thymidine phosphorylase (TP) in tumour compared with normal
tissue (Miwa et al, 1998; Schu ¨ller et al, 2000). After oral
administration, capecitabine is rapidly and virtually completely
absorbed intact through the gastrointestinal wall and metabolised
to 5-FU via a three-step enzymatic cascade. In the final step, 5-FU
is generated preferentially at the tumour site due to the
significantly higher TP activity in tumour tissue. This potentially
improves efficacy and safety. Single-agent capecitabine is con-
sidered by many to be the reference treatment for patients with
taxane-pretreated MBC. In four trials conducted in a total of 500
patients with anthracycline- and taxane-pretreated disease, cape-
citabine achieved objective response rates ranging from 15 to 28%,
overall disease control rates of 57–63% and median overall
survival of approximately 12 months (Blum et al, 1999, 2001a;
Fumoleau et al, 2004; Reichardt et al, 2003). In addition,
capecitabine demonstrated a favourable safety profile, with a
particularly low incidence of myelosuppression, severe adverse
events and alopecia.
Received 27 May 2003; revised 12 January 2004; accepted 19 February
2004; published online 6 April 2004
*Correspondence: Dr N Batista; E-mail: nbatista@ull.es
British Journal of Cancer (2004) 90, 1740–1746
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $25.00
www.bjcancer.com
C
l
i
n
i
c
a
lThere is a clear rationale behind the evaluation of capecitabine/
taxane combinations in patients with breast cancer. With a low
incidence of myelosuppression, capecitabine is an ideal agent for
incorporation into combination regimens with myelosuppressive
agents such as the taxanes. In addition, preclinical studies show
that many cytotoxic agents, including paclitaxel and docetaxel,
upregulate TP in tumour tissue and have synergistic antitumour
activity when combined with capecitabine (Sawada et al, 1998;
Ishitsuka, 2000).
Paclitaxel has demonstrated efficacy across a variety of
treatment schedules and is commonly administered in patients
with anthracycline-pretreated MBC (Seidman et al, 1995a,b). A
phase I study demonstrated that a 3-weekly regimen combining i.v.
paclitaxel, administered on day 1 as a 3-h infusion, with oral
capecitabine, administered twice daily on days 1–14, is feasible
and clinically active in patients with pretreated MBC. No
significant pharmacokinetic interactions between the two agents
were reported (Villalona-Calero et al, 2001). The principal dose-
limiting toxicities of the combination therapy were the cutaneous
side effect hand–foot syndrome, which is characteristic of
protracted infused fluoropyrimidines or capecitabine (which was
designed to mimic continuous infusion of 5-FU), and neutropenia,
which is dose limiting with single-agent paclitaxel.
The current phase II study was performed to evaluate the
efficacy and safety of capecitabine plus 3-weekly paclitaxel in
patients with anthracycline-pretreated advanced or MBC.
PATIENTS AND METHODS
Study design
This open-label, phase II trial of intermittent, oral capecitabine in
combination with i.v. paclitaxel in patients with anthracycline-
pretreated advanced/MBC was conducted between August 1998
and 2000 in accordance with the International Good Clinical
Practice Principles and local ethical and regulatory requirements.
All patients provided written informed consent before screening
and enrolment. The primary objective of the study was to assess
the antitumour activity of the capecitabine/paclitaxel regimen,
determined by objective response rate. Secondary objectives were
to evaluate duration of response, TTP, overall survival and safety.
Oral capecitabine 1000mgm
 2 was administered twice daily on
days 1–14 of each 3-week treatment cycle. Paclitaxel 175mgm
 2
was administered as a 3-h infusion on day 1 of each treatment
cycle. It was recommended that all patients receive routine
prophylactic corticosteroid, antihistamine and H2-receptor an-
tagonist premedication before the administration of paclitaxel.
Additional permitted supportive treatment and concomitant
medication were administered as required at the investigator’s
discretion. Haemopoietic growth factors could be used to treat
symptomatic neutropenia.
Duration of treatment depended on tumour response: patients
with stable disease or a partial response (PR) received a maximum
of 10 cycles of chemotherapy, and patients with a complete
response (CR) received four cycles of chemotherapy following
confirmation of CR. Upon documentation of disease progression
study treatment was discontinued.
Patient population
The study was conducted in women with histologically confirmed,
bidimensionally measurable breast cancer that had progressed
during or following anthracycline-containing therapy adminis-
tered in the adjuvant or metastatic setting. Patients were required
to meet the following eligibility criteria: age 18–70 years, life
expectancy 43 months, Karnofsky performance status (KPS)
X60%, absolute neutrophil count (ANC) X1500ml
 1, platelet
count X100000ml
 1, total bilirubin o1.5 the upper normal limit
(UNL), aspartate transaminase (ASAT) and/or alanine transami-
nase (ALAT) p5 UNL, alkaline phosphatase p5 UNL
(although this was permitted if bone metastases were present
and there was no evidence of a liver disorder) and serum
creatinine concentration p133mmoll
 1. Patients were excluded
if they had been previously exposed to paclitaxel in the adjuvant or
metastatic setting and if they had previously received more than
two chemotherapy regimens for treatment of metastatic disease.
Prior docetaxel treatment was permitted. Previous cytotoxic
chemotherapy or hormonal therapy was to have been completed
46 weeks or 410 days, respectively, prior to the initiation of
study treatment. In addition, patients were to have received no
transfused blood products or haematopoietic growth factors
during the 2 weeks prior to the start of study treatment.
The following patients were excluded from the study: pregnant
or lactating patients; women of childbearing potential who lacked a
reliable method of contraception; patients with a history of
seizures, CNS disorders or psychiatric disability; patients with CNS
metastases; and patients who showed evidence of any other serious
illness or medical condition, including serious uncontrolled
infections. Patients with clinically significant cardiac disease, as
defined by symptomatic ventricular arrhythmias, history of
congestive heart failure or previous myocardial infarction within
12 months of study enrolment were excluded, as were patients with
malabsorption syndromes or a history of previous gastrointestinal
surgery affecting oral absorption. Additional exclusion criteria
included a history of: organ allograft; another malignancy within 5
years of study entry (except basal cell carcinoma of the skin or
carcinoma in situ of the uterine cervix); severe and unexpected
reaction to paclitaxel (or its formulation constituents) or
fluoropyrimidine therapy (with or without documented dihydro-
pyrimidine dehydrogenase deficiency); and a known hypersensi-
tivity to 5-FU.
At the time the study was started, data showing the impact of
moderate/severe renal impairment on the safety of capecitabine
were not available. However, the protocol recommended caution
when administering capecitabine in patients with moderate/severe
renal impairment. More recent data led to contraindication of
capecitabine in patients with severe renal impairment (defined as
creatinine clearance o30mll
 1) and a 25% reduction of the
capecitabine starting dose in patients with moderate impairment
(creatinine clearance 30–50mll
 1) at baseline (Cassidy et al,
2002).
Dose modification
Treatment was continued at the same dose (without interruption
or dose reduction) if patients experienced Grade 1 toxicities or
other toxicities considered unlikely to become serious or life
threatening (e.g. alopecia). For all other treatment-related adverse
events with intensity of Grade 2 or higher (except Grade 3
peripheral neuropathy, severe fluid retention, hypersensitivity
reactions, hepatic impairment or neutropenia, as described below),
the following dose modification scheme was implemented. Dose
reduction was not required following the first appearance of any
Grade 2 toxicity, although treatment was interrupted/delayed until
the toxicity had resolved to Grades 0–1 and symptomatic
treatment was initiated when possible. Treatment with both agents
was interrupted/delayed and the dose of both agents was reduced
by 25% in patients who experienced a second occurrence of a given
Grade 2 toxicity or at the first occurrence of a Grade 3 toxicity. If
patients experienced a third occurrence of a given Grade 2 toxicity
or a second occurrence of a given Grade 3 toxicity, treatment was
interrupted/delayed until the toxicity resolved to Grades 0–1 and
the dose of capecitabine was reduced by 50% and paclitaxel
discontinued. Treatment with both agents was discontinued if,
despite dose reduction, a given toxicity occurred for a fourth time
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lat Grade 2 or a third time at Grade 3. Treatment was also
discontinued if patients experienced a Grade 4 nonhaematological
toxicity, unless the investigator considered it to be in the best
interest of the patient to continue treatment with single-agent
capecitabine at 50% of the original dose.
Paclitaxel was discontinued and capecitabine treatment was
modified according to the scheme outlined above in patients
experiencing Grade 3 peripheral neuropathy or severe fluid
retention (e.g. pleural effusion, pericardial effusion or ascites).
Patients developing severe hypersensitivity reactions (e.g. blood
pressure decreased by X20mgm
 2, bronchospasm or generalised
rash/erythema) during or following paclitaxel administration were
taken off study immediately and given appropriate therapy. In
patients developing Grade 2 elevations in transaminase (ASAT
and/or ALAT) concentrations with a Grade 2 elevation in alkaline
phosphatase concentration, the dose of paclitaxel was reduced by
25%. Paclitaxel treatment was interrupted in patients experiencing
Grade 3 elevations in these enzymes and discontinued if the liver
function had not recovered within 2 weeks of the interruption.
In the case of neutropenia, paclitaxel was readministered only
when ANC recovered to X1.5 10
9l
 1. In patients experiencing
Grade 4 neutropenia (ANC p0.5 10
9l
 1) for more than 7 days or
febrile (X381C) neutropenia, the dose of paclitaxel was reduced by
25%. Paclitaxel was discontinued if patients receiving the reduced
dose experienced Grade 4 neutropenia or febrile neutropenia. As
capecitabine was not expected to worsen or prolong neutropenic
episodes, capecitabine treatment could be continued during
episodes of Grade 3–4 neutropenia. However, capecitabine was
to be interrupted upon the development of any other Grade 2
toxicity during the neutropenic episode, with the patient closely
monitored in hospital. The next cycle was not started until
neutropenia had resolved to Grades 0–1.
Patient evaluation
Tumour evaluation, based on WHO criteria (WHO, 1979), was
performed at baseline and at 6-weekly intervals during the study
period. The best overall response was defined as the best response
recorded from the start of treatment to disease progression.
Complete response and PR were confirmed by a second tumour
assessment after X4 weeks. For patients demonstrating an
objective response, the time to response was defined as the
interval between the start of treatment and the first observation of
response. In patients achieving a CR or PR, the duration of
response was defined as the time interval between the start of
treatment and the first observation of disease progression or, in
patients with no documented disease progression, death or last
contact. Time to progression was defined as the interval between
the start of treatment and disease progression (or death or last
contact in patients with no documented disease progression) in all
patients. Overall survival was defined as the interval between the
start of treatment and death.
Safety was evaluated in all patients receiving at least one dose of
study treatment. Adverse events (with the exception of hand–foot
syndrome) and abnormal laboratory parameters were graded
according to the National Cancer Institute of Canada Common
Toxicity Grade (NCIC CTG). Hand–foot syndrome was graded 1–
3 using established criteria (Blum et al, 1999; Blum, 2001). The
nature, severity and outcome of all adverse events occurring
during treatment were recorded.
Statistical analysis
Sample size was calculated based on the method of Fleming (1982).
In advanced breast cancer, a response rate of 20% can be
considered of little interest, while 40% or more can be considered
encouraging. With a power of 95% and a one-sided significance
level of 5%, a total of 54 patients was required. Assuming a 15%
dropout rate, a target of 64 patients for recruitment was adopted.
All efficacy analyses were performed using the ITT population.
Time to progression, duration of response and overall survival
were estimated by Kaplan–Meier analysis.
RESULTS
Patient demographics and baseline disease characteristics
Patient characteristics are summarised in Table 1. A total of 73
patients with a median age of 52 years (range 33–74 years) were
enrolled in the study at 13 centres in Spain and Sweden. The
median KPS was 90% (range 60–100%), with KPS X80% in the
majority of patients (89%). Approximately two-thirds of the
patients (63%) had multiple sites of metastasis. The most common
metastatic sites were bone (45% of patients), liver (44%), lymph
nodes (40%) and lung (34%).
As predefined in the protocol, all patients had received prior
anthracycline therapy. Of the 34 patients pretreated with
anthracyclines in the metastatic setting, three had also received
neoadjuvant or adjuvant anthracyclines.
A total of 512 cycles of chemotherapy (combination or
capecitabine monotherapy) were administered, with a median of
eight treatment cycles per patient (range 1–11). All 73 patients
received at least one dose of study therapy and were therefore
evaluable for safety. The majority of patients who withdrew from
treatment with either agent stopped receiving both treatments, so
that very few patients received either capecitabine or paclitaxel
monotherapy during any cycle (Table 2). One patient received
paclitaxel monotherapy and withdrew during the first cycle
without receiving capecitabine.
Efficacy
Overall, the capecitabine/paclitaxel regimen demonstrated an
objective response rate of 52% (95% CI: 40–63), with CR in eight
Table 1 Patient and baseline disease characteristics (n¼73)
Median age (years) (range) 52 (33–74)
KPS, no. (%) of patients
100 31 (42)
90 19 (26)
80 15 (21)
70 7 (10)
60 1 (1)
Number of metastatic sites, no. (%) of patients
a
1 26 (36)
2 25 (34)
X3 21 (29)
Sites of metastasis, no. (%) of patients
a
Bone 33 (45)
Liver 32 (44)
Lymph nodes 29 (40)
Lung 25 (34)
Prior chemotherapy
Anthracyclines, no. (%) of patients 73 (100)
(Neo)adjuvant setting 42 (58)
Metastatic setting 34 (47)
Docetaxel, no. (%) of patients 11 (15)
Cyclophosphamide, no. (%) of patients 38 (52)
5-FU, no. (%) of patients 31 (42)
aConfirmation of metastatic disease was not available in one patient. KPS¼Karnofsky
performance status; 5-FU¼5-fluorouracil.
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lpatients (11%) and PR in 30 patients (41%) (Table 3). Disease was
stabilised in a further 21 patients (29%). Retrospective analyses
revealed no differences in response rates between subpopulations:
response rates were similarly high in patients pretreated with
anthracyclines in the (neo)adjuvant setting only (n¼39) (59%;
95% CI: 42–74) and metastatic setting (n¼34) (42%; 95% CI: 26–
61). Of the 11 patients pretreated with docetaxel in the metastatic
setting, four (36%) achieved an objective response and disease was
stabilised in a further five patients (45%).
The median follow-up at the time of data analysis was 8.0
months (range 0.2–24.5 months) and disease progression or death
had occurred in 54 patients during this period. The median TTP
for all patients was 8.1 months (95% CI: 6.2–9.2) (Figure 1) and
median duration of response in the 38 responding patients was
10.6 months (95% CI: 8.7–11.4) (Figure 2). Median overall survival
was 16.5 months (95% CI: 12.6–20.0) (Figure 3).
Safety
Apart from alopecia, which is commonly associated with
paclitaxel-containing therapies and occurred in a substantial
proportion of patients (30%), the most frequent (420% of
patients) treatment-related, clinical adverse events were hand–
foot syndrome (42%), diarrhoea (26%), myalgia (25%), vomiting
(23%), neurotoxicity (21%) and asthenia (21%) (Table 4). The
majority of treatment-related adverse events were mild to
moderate in intensity. The only treatment-related Grade 3/4
clinical adverse events occurring in more than 5% of patients
were alopecia (22%, Grade 3 only) and hand–foot syndrome (11%,
Grade 3 only). Grade 3/4 treatment-related diarrhoea occurred in
Table 2 Patients receiving capecitabine plus paclitaxel combination
therapy or monotherapy with either agent at each cycle
Cycle
number
Combination
therapy
Capecitabine
monotherapy
Paclitaxel
monotherapy Off study
17 2 0 1 0
26 9 0 0 4
36 3 0 1 9
45 9 0 0 1 4
55 3 0 2 1 8
64 8 1 2 2 2
74 1 0 3 2 9
83 4 1 3 3 5
10 27 1 1 44
No data available for cycle 9.
Table 3 Antitumour activity (Intent-to-treat population, n¼73)
No. of patients % of patients (95% CI)
Objective response 38 52 (40–63)
CR 8 11 (5–21)
PR 30 41 (29–53)
Stable disease 21 29 (20–43)
CI¼confidence interval; CR¼complete response; partial response.
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Table 4 Most frequent (affecting 410% patients) treatment-related
clinical adverse events (n¼73)
NCIC-CTG grade: no. (%) of patients
Grade 1/2 Grade 3 Grade 4
Hand–foot syndrome
a 23 (32) 8 (11) —
Alopecia 6 (8) 16 (22) —
Diarrhoea 17 (23) 1 (1) 1 (1)
Myalgia 18 (25) — —
Vomiting 15 (21) 1 (1) 1 (1)
Neurotoxicity 13 (18) 2 (3) —
Asthenia 15 (21) — —
Nausea 11 (15) — —
Paraesthesia 9 (12) 1 (1) —
Mucositis 6 (8) 1 (1) 1 (1)
NCIC CTG¼National Cancer Institute of Canada Common Toxicity Grade.
aGraded 1–3 using established criteria (Blum 2001; Blum et al, 1999).
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lonly two patients (Grade 3 in one patient, Grade 4 in the other).
Grade 3/4 neurotoxicity was also rare with the capecitabine/
paclitaxel combination: only one patient experienced Grade 4
peripheral neuropathy and there was only one case of Grade 3
paraesthesia.
The most common Grade 4 haematological abnormality was
neutropenia, which occurred in 5% of patients (Table 5). Grade 3/4
lymphocytopenia occurred in 10 patients (14%). There was a low
incidence of Grade 3/4 thrombocytopenia (two patients, 3%) and
Grade 3/4 anaemia was not observed. Febrile neutropenia was
reported in only three patients (4%). Two patients received G-CSF
for the treatment of neutropenia (one patient with Grade 3
leucopenia and Grade 2 fever and the other with Grade 3 febrile
neutropenia). In addition, one patient received prophylactic
G-CSF.
A total of 44 patients (60%) withdrew from the study before
completion of treatment, more than half (23 patients, 52%) due to
disease progression. A further 13 patients (30%) withdrew due to
adverse events. No treatment-related deaths occurred during the
study, but two patients died due to disease progression before
completing treatment.
DISCUSSION
Currently, the taxanes are the most widely used agents for the
treatment of patients with anthracycline-pretreated advanced/
MBC. Paclitaxel was the first taxane to show activity in MBC
(Holmes et al, 1991) and has demonstrated activity in anthracy-
cline-pretreated patients in a number of phase II trials, with
response rates varying from 17 to 53% (Abrams et al, 1995; Dieras
et al, 1995; Gianni et al, 1995; Fountzilas et al, 1996; Nabholtz et al,
1996; Holmes et al, 1998; Seidman et al, 1998; Smith et al, 1999).
The efficacy of single-agent paclitaxel has not been definitively
evaluated vs a standard salvage therapy in a randomised, phase III
trial, however. Although paclitaxel has demonstrated efficacy in
phase III trials in the first-line setting (Paridaens et al, 2000; Sledge
et al, 2003), the optimal dose schedule for single-agent adminis-
tration has not been fully established. The most widely used
regimen is a 3-weekly schedule of 135–175mgm
 2, although
weekly administration of paclitaxel has also been evaluated
(Seidman et al, 1998). With the weekly schedule, there was
relatively little myelosuppression, but peripheral neuropathy
prevented dose escalation above 100mgm
 2.
Attempts to increase the efficacy of paclitaxel have largely
focused on its use in combination regimens. However, the side
effect profile of paclitaxel, which includes a high rate of
myelosuppression, has limited its use in combination regimens
with other myelosuppressive drugs. Since capecitabine is asso-
ciated with a very low incidence of myelosuppression, its use as a
combination partner for paclitaxel in the current study (along with
the administration of G-CSF support) may explain the relatively
low incidence of severe myelosuppression experienced by patients.
The current study shows that capecitabine in combination with
3-weekly paclitaxel is highly active in patients with anthracycline-
pretreated MBC, consistent with the findings of O’Shaughnessy
et al (2002) with capecitabine plus docetaxel. The present regimen
resulted in a high rate of disease control in these patients, with
objective responses in 52% of patients and disease stabilisation in a
further 29%. Furthermore, objective response rates appear similar
in the subpopulations of patients pretreated with anthracyclines
only in the (neo)adjuvant setting (59%) or in the metastatic setting
(42%). Although there was a trend toward a higher response rate in
the subpopulation pretreated with (neo)adjuvant anthracyclines,
the difference was not statistically significant. In addition to the
impressive rate of tumour control, time-dependent outcomes with
the combination were very encouraging, with a median TTP of 8.1
months, a median duration of response of 10.6 months and a
median overall survival of 16.5 months.
Capecitabine/paclitaxel combination therapy is generally well
tolerated, demonstrating a predictable safety profile consistent
with the safety profiles of the component agents. The most
common treatment-related adverse event was hand–foot syn-
drome, a cutaneous side effect that is characteristic of prolonged
cytostatic administration. The majority of cases of hand–foot
syndrome were mild to moderate in intensity, and only eight
patients (11%) experienced severe hand–foot syndrome. The
incidence of hand–foot syndrome was thus in a similar range to
that observed by Blum et al (1999) with capecitabine monotherapy
(1250mgm
 2 twice daily). Previous studies have shown that this
side effect is readily manageable with capecitabine treatment
interruption and dose modification, if necessary (Blum, 2001;
Blum et al, 2001b). Based on the safety profiles of single-agent
capecitabine and paclitaxel, gastrointestinal side effects were also
anticipated with the combination. However, fewer episodes of
diarrhoea, nausea and vomiting occurred than are usually seen
with standard-dose monotherapy with either agent. These were not
problematic and were effectively managed by dose modification,
supportive care and pharmacological interventions.
Grade 3/4 treatment-related diarrhoea and vomiting were each
reported by only two patients. Neurological side effects have been
frequently reported with paclitaxel, although in our study, asthenia
generally occurred at only mild–moderate intensity. Severe (Grade
3) neurotoxicity was reported in only two patients (3%).
Neutropenia, which is also commonly associated with paclitaxel
treatment, was effectively managed in the majority of cases
(including the curative use of G-CSF in two patients). Continuation
of capecitabine therapy in patients with Grade 3/4 neutropenia did
not appear to compromise haematological recovery.
The results of the current study are supported by the
preliminary data of a phase II study evaluating a similar regimen
(capecitabine 825mgm
 2 twice daily, days 1–14 in combination
with paclitaxel 175mgm
 2 on day 1) in patients with predomi-
nantly untreated MBC (Gradishar et al, 2003). In this study, an
objective response rate of 51% was reported, almost identical to
that observed in the current study, with a median TTP of 10.6
months and a median overall survival of 29.9 months. The long
overall survival possibly reflects the fact that patients had received
less extensive pretreatment than those in the current study. A
similar safety profile was observed in both studies. A phase I/II
trial is also evaluating the feasibility of capecitabine with weekly
paclitaxel.
Paclitaxel has also been studied in combination with gemcita-
bine vs paclitaxel alone as first-line treatment for MBC in a phase
III study (O’Shaughnessy et al, 2003). All patients were pretreated
with anthracyclines in the adjuvant setting. Gemcitabine plus
paclitaxel showed disappointing results achieving an overall
response rate of 39% compared with 26% with paclitaxel alone.
The median TTP was 5.4 months with gemcitabine/paclitaxel vs 3.5
months with paclitaxel alone. The median overall survival has not
been reached. The gemcitabine/paclitaxel combination does not
Table 5 Incidence of treatment-related Grade 3/4 haematological
adverse events (n¼73)
NCIC-CTC grade: no. (%) of patients
Adverse event Grade 3 Grade 4
Lymphocytopenia 7 (10) 3 (4)
Neutropenia 5 (7) 4 (5)
Leucopenia 7 (10) 2 (3)
Neutropenic fever 2 (3) 1 (1)
Thrombocytopenia 1 (1) 1 (1)
NCIC CTC¼National Cancer Institute of Canada Common Toxicity Criteria.
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lappear to be as effective as the capecitabine/paclitaxel combination
(response rate of 52%, median TTP 8.1 months) presented here.
The efficacy of the capecitabine/paclitaxel combination is very
promising, comparing favourably with that reported for capecita-
bine/docetaxel in anthracycline-pretreated MBC (response rate
42%, median TTP 6.1 months and median overall survival 14.5
months) (O’Shaughnessy et al, 2002). Further evaluation of the
capecitabine/paclitaxel combination vs capecitabine/docetaxel,
which is now considered the ‘gold standard’ chemotherapy for
anthracycline-pretreated MBC, is warranted.
In summary, the results of this phase II study demonstrate that
capecitabine plus paclitaxel is highly effective with a favourable
safety profile in patients with anthracycline-pretreated advanced/
MBC. Phase III evaluation of this regimen is now required to
establish definitively the efficacy of this combination in patients
with advanced/MBC.
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